Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Merck
Mallinckrodt
Citi
US Department of Justice
Healthtrust
Moodys
Fuji
McKesson
Cipla

Generated: August 17, 2017

DrugPatentWatch Database Preview

BOEHRINGER INGELHEIM Company Profile

« Back to Dashboard

What is the competitive landscape for BOEHRINGER INGELHEIM, and what generic alternatives to BOEHRINGER INGELHEIM drugs are available?

BOEHRINGER INGELHEIM has forty-nine approved drugs.

There are one hundred and three US patents protecting BOEHRINGER INGELHEIM drugs and there have been four Paragraph IV challenges on BOEHRINGER INGELHEIM drugs in the past three years. There is one tentative approval on BOEHRINGER INGELHEIM drugs.

There are two thousand four hundred and forty-nine patent family members on BOEHRINGER INGELHEIM drugs in sixty-eight countries.

Summary for Applicant: BOEHRINGER INGELHEIM

Patents:103
Tradenames:40
Ingredients:30
NDAs:49
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
GLYXAMBI
empagliflozin; linagliptin
TABLET;ORAL206073-001Jan 30, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
JENTADUETO XR
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208026-002May 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747-001Oct 7, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
STIOLTO RESPIMAT
olodaterol hydrochloride; tiotropium bromide
SPRAY, METERED;INHALATION206756-001May 21, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
SYNJARDY XR
empagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208658-002Dec 9, 2016RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Boehringer Ingelheim

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
STIOLTO RESPIMAT
olodaterol hydrochloride; tiotropium bromide
SPRAY, METERED;INHALATION206756-001May 21, 2015► Subscribe► Subscribe
Boehringer Ingelheim
MIRAPEX
pramipexole dihydrochloride
TABLET;ORAL020667-001Jul 1, 1997► Subscribe► Subscribe
Boehringer Ingelheim
COMBIPRES
chlorthalidone; clonidine hydrochloride
TABLET;ORAL017503-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-1
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-001Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
MICARDIS
telmisartan
TABLET;ORAL020850-001Nov 10, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BOEHRINGER INGELHEIM drugs

Drugname Dosage Strength Tradename Submissiondate
dabigatran etexilate mesylate
Capsuleseq. to 110 mg base
PRADAXA
12/15/2015
linagliptin
Tablets5 mg
TRADJENTA
5/4/2015
linagliptin and metformin hydrochloride
Tablets2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg
JENTADUETO
5/4/2015
dabigatran etexilate mesylate
Capsuleseq. to 75 mg base and 150 mg base
PRADAXA
10/20/2014
nevirapine
Extended-release Tablets400 mg
VIRAMUNE XR
6/21/2013
pramipexole dihydrochloride
Extended-release Tablets2.25 mg and 3.75 mg
MIRAPEX ER
7/26/2011
pramipexole dihydrochloride
Extended-release Tablets0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg
MIRAPEX ER
6/1/2010
meloxicam
Oral Suspension7.5 mg/5 mL
MOBIC
12/17/2009
telmisartan and hydrochlorothiazide
Tablets80 mg/25 mg
MICARDIS HCT
2/27/2009
telmisartan and hydrochlorothiazide
Tablets80 mg/12.5 mg and 40 mg/12.5 mg
MICARDIS HCT
12/31/2008
pramipexole dihydrochloride
Tablets0.75 mg
MIRAPEX
7/31/2008
aspirin and dipyridamole
Extended-release Capsules25 mg and 200 mg
AGGRENOX
2/1/2007
telmisartan
Tablets20 mg, 40 mg and 80 mg
MICARDIS
12/26/2006
pramipexole dihydrochloride
Tablets0.125 mg, 0.5 mg, 1 mg and 1.5 mg
MIRAPEX
6/24/2005
pramipexole dihydrochloride
Tablets0.25 mg
MIRAPEX
5/27/2005
tamsulosin hydrochloride
Capsules0.4 mg
FLOMAX
12/20/2004

Non-Orange Book Patents for Boehringer Ingelheim

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,503,440 Process for making a container with a pressure equalization opening and containers produced accordingly► Subscribe
6,469,039 Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions► Subscribe
8,541,450Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines► Subscribe
5,547,094 Method for producing atomizing nozzle assemblies► Subscribe
6,585,959 Process for preparing powder formulations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Boehringer Ingelheim Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)9855107► Subscribe
China102167695► Subscribe
Yugoslavia59101► Subscribe
China103467423► Subscribe
European Patent Office2060573► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Boehringer Ingelheim Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014005Lithuania► SubscribePRODUCT NAME: AFATINIBUM; REGISTRATION NO/DATE: EU/1/13/879/001-EU/1/13/879/012 20130925
C/GB14/083United Kingdom► SubscribePRODUCT NAME: ALOGLIPTIN; REGISTERED: UK EU/1/13/844 20130923
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
00445Netherlands► SubscribePRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
2014035Lithuania► SubscribePRODUCT NAME: EMPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/14/930 20140522
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Merck
UBS
Mallinckrodt
McKesson
Farmers Insurance
Chinese Patent Office
AstraZeneca
Covington
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot